Your AI-Trained Oncology Knowledge Connection!
The addition of vopratelimab to pimivalimab did not elicit a significant mean percent change of baseline tumor size in all measurable lesions vs pimivalimab alone in patients with immunotherapy-naïve, metastatic non–small cell lung cancer who were positive for the TISvopra predictive biomarker.
Sotorasib demonstrated superiority and a statistically significant benefit in progression-free survival vs standard-of-care docetaxel in previously treated patients with KRAS G12C–mutated non–small cell lung cancer.
Subcutaneous administration of isatuximab through a syringe pump or on-body delivery system demonstrated similar efficacy and safety compared with intravenous isatuximab when combined with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
The combination of gefitinib plus chemotherapy generated a benefit in time to second progression vs gefitinib alone in untreated patients with EGFR-mutated non–small cell lung cancer.
Treatment with either encorafenib plus cetuximab with or without binimetinib or standard chemotherapy each demonstrated comparable progression-free survival and overall survival in pretreated patients with BRAF V600E–mutated metastatic colorectal cancer.
The FDA has granted permission for enrollment to resume in the monotherapy phase 1a portion of the phase 1/2 TakeAim Leukemia trial evaluating emavusertib in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
Rami Komrokji, MD, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes, and highlights other key updates in chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and myelofibrosis.
Antoinette Stroup, PhD, shares personal and professional insight on the disaggregation of cancer health statistics regarding the Asian American and Pacific Islander community.
Daiichi Sankyo submitted a supplemental new drug application to Japan’s Ministry of Health, Labor, and Welfare for the use of quizartinib in patients with newly diagnosed, FLT3-ITD–positive acute myeloid leukemia.
Treatment with soluble EphB4-human serum albumin plus pembrolizumab elicited synergistic activity and an improved overall survival and objective response rate compared with historical data for PD-1/PD-L1 monotherapy in patients with platinum-refractory metastatic urothelial carcinoma.
Several inroads have been made in the realm of gastrointestinal cancers, with novel immunotherapy combinations representing a significant advance spanning several tumor types.
The combination of plinabulin and pegfilgrastim was well tolerated patients with multiple myeloma who have undergone autologous hematopoietic stem cell transplantation and who have received a high dose of melphalan.
Shanu Modi, MD, discusses the significance of the approval of trastuzumab deruxtecan for patients with HER2-low breast cancer.
Judy C. Boughey, MD, shares criteria for omission of sentinel lymph node surgery, the importance of not altering treatment based on identification of variants of uncertain significance, and the potential value of trastuzumab deruxtecan in HER2-low metastatic breast cancer.
The European Commission has approved asciminib for the treatment of patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase who received prior treatment with at least 2 TKIs
The new proposal will have grave effects on the sustainability of community oncology practices.
Matthew P. Goetz, MD, discusses overall survival data with ribociclib and abemaciclib in estrogen receptor–positive, HER2-negative disease; the role of adjuvant pembrolizumab in patients with triple-negative breast cancer; and the efficacy of PARP inhibitors in earlier settings.
Ciltacabtagene autoleucel elicited high rates of minimal residual disease negativity in patients with heavily pretreated multiple myeloma who received prior treatment with a BCMA-targeted therapy.
Ciltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.
Identifying BCMA expression, copy number variation, and point mutations can have important therapeutic implications for patients receiving BCMA-targeting CAR T-cell therapy or T-cell engagers for multiple myeloma.
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) induction and consolidation treatment and lenalidomide maintenance therapy (D-RVd/D-R) resulted in high minimal residual disease rates and prolonged progression-free survival in patients with transplant-eligible, newly diagnosed multiple myeloma.
High-dose busulfan plus melphalan failed to generate a progression-free survival benefit vs melphalan for autologous stem cell transplant conditioning in patients with newly diagnosed multiple myeloma after induction therapy.
Promising safety and efficacy results were observed with the novel bispecific antibody ABBV-383 in patients with heavily pretreated relapsed or refractory multiple myeloma.
Relapse following treatment with BCMA-directed CAR T-cell therapy was associated with poor survival outcomes in patients with relapsed/refractory multiple myeloma.
The addition of isatuximab to pomalidomide and low-dose dexamethasone continued to demonstrate improved overall survival in patients with relapsed/refractory multiple myeloma.
The addition of isatuximab to carfilzomib and dexamethasone elicited a clinically meaningful improvement in depth of response in patients with relapsed multiple myeloma.
REGN5458 produced durable responses with low rates of cytokine release syndrome in patients with relapsed/refractory multiple myeloma.
Agents with novel mechanisms, including bispecific antibodies, immunomodulatory drugs, and antibody-drug conjugates, are displaying promising results in patients with relapsed or refractory multiple myeloma.
Cevostamab generated responses and was well tolerated in younger and older patients with relapsed/refractory multiple myeloma.
Baseline ocular conditions not related to the cornea have little effect on treatment-emergent adverse effects that may arise with belantamab mafodotin in patients with relapsed/refractory multiple myeloma.
